Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Onglyza (saxagliptin) - Important Safety Information from Bristol-Myers Squibb as approved by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
12/03/2012
Problem Or Issue:
Important Safety Information communication from Bristol-Myers Squibb on the association of Onglyza (saxagliptin) with serious hypersensitivity reactions and acute pancreatitis.
Important Safety Information - Onglyza
« Back
Date Printed: 06/05/2024